Pirtobrutinib

Brand names: Jaypirca · Active ingredient: Pirtobrutinib

In short: JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate .

Forms & strengthsTablets: Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side. Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on one side and “7026” on the other side.
LabelEli Lilly and Company
Label updatedOct 19, 2026

What is Pirtobrutinib used for?

JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.

JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.

Pirtobrutinib dosage

The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity.

Advise patients of the following:

Swallow tablets whole with water. Do not cut, crush, or chew tablets.

Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food .

If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.

Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in Table 1

.

Dose modification is not recommended for asymptomatic lymphocytosis. Asymptomatic lipase increase may not necessarily warrant dose modification.

a Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity.

Adverse Reaction | Occurrences Requiring Dosage Modification | Modification

(Starting Dosage: 200 mg once daily)

Grade 3 or greater non-hematologic toxicity a

Absolute neutrophil count < 1 to 0.5 x 109/L with fever and/or infection

Absolute neutrophil count < 0.5 x 109/L lasting 7 or more days

Platelet count < 50 to 25 x 109/L with bleeding

Platelet count < 25 x 109/L | First occurrence | Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily)a.

Second occurrence | Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily.

Third occurrence | Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily.

Fourth occurrence | Discontinue JAYPIRCA.

For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA . No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).

Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA . If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50 mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.

Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA . If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.

How to take Pirtobrutinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Infections

Advise patients that JAYPIRCA can cause serious infections that may be fatal. Advise patients to report any signs or symptoms of infection (e.g., fever, chills, weakness) .

Hemorrhage

Inform patients to report signs or symptoms of bleeding. Inform patients that JAYPIRCA may need to be interrupted for major surgeries .

Cytopenias

Advise patients of the need for periodic monitoring of blood counts during treatment with JAYPIRCA .

Cardiac Arrhythmias

Counsel patients to report any signs of palpitations, dizziness, fainting, chest discomfort, and shortness of breath .

Second Primary Malignancies

Inform patients that other malignancies have been reported in patients who have been treated with JAYPIRCA, including skin cancer and other solid tumors. Advise patients to use sun protection and to have monitoring for development of other cancers .

Hepatotoxicity, Including Drug-Induced Liver Injury

Inform patients that liver problems, including severe, life-threatening, or fatal hepatitis, drug-induced liver injury and abnormalities in liver tests, may develop during JAYPIRCA treatment. …

Warnings & precautions

Do not take this medicine if: None.

Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. Across all clinical trials, Grade 3 or higher infections occurred in 23% of 1153 patients, most commonly pneumonia (13%), with fatal infections occurring in 4.3% of patients. Sepsis occurred in 4.8% of patients and febrile neutropenia in 3.3%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 24% of patients, with fatal infections occurring in 5%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, Pneumocystis jirovecii pneumonia and fungal infection .

Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA .

Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3.1% of 1153 patients treated with JAYPIRCA across all clinical trials, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients. Bleeding of any grade, excluding bruising and petechiae, occurred in 18% of patients .

Major hemorrhage occurred in 1.8% of patients taking JAYPIRCA without antithrombotic agents and 1.3% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA . …

Pirtobrutinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Infections

Hemorrhage

Cytopenias

Atrial Fibrillation and Atrial Flutter

Second Primary Malignancies

Hepatotoxicity, including DILI

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.

The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200 mg once daily in 1153 patients with hematologic malignancies in the four clinical studies. Among these 1153 patients, the median duration of exposure was 18 months; 76% were exposed for at least 6 months and 66% were exposed for at least one year.

In this pooled safety population, the most common (≥ 30%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (56%) and decreased hemoglobin (38%).

Mantle Cell Lymphoma

BRUIN

The safety of JAYPIRCA was evaluated in the BRUIN trial, an open-label, multicohort, single-arm study in patients with previously treated MCL who received a prior BTK inhibitor . The trial required a platelet count ≥ 50 x 109/L, absolute neutrophil count ≥ 0.75 x 109/L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. …

Drug interactions

Strong CYP3A Inhibitors

Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure , which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the JAYPIRCA dosage .

Strong or Moderate CYP3A Inducers

Concomitant use of JAYPIRCA with a strong or moderate CYP3A inducer decreased pirtobrutinib systemic exposure , which may reduce JAYPIRCA efficacy. Avoid concomitant use of JAYPIRCA with strong or moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dosage .

Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates

JAYPIRCA is a P-gp inhibitor, a moderate CYP2C8 and BCRP inhibitor, and a weak CYP2C19 and CYP3A inhibitor. Concomitant use of JAYPIRCA with sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates increased their plasma concentrations , which may increase the risk of adverse reactions related to these substrates for drugs which are sensitive to minimal concentration changes. …

About this medicine

Pirtobrutinib is a kinase inhibitor. It is an orally available, small molecule ATP-competitive inhibitor of BTK. The active pharmaceutical ingredient is pirtobrutinib with the molecular formula C22H21F4N5O3 and a molecular weight of 479.44 g/mol. The chemical name for pirtobrutinib is 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide.

Pirtobrutinib is a white to practically white to yellow to brown solid. The aqueous solubility of pirtobrutinib is considered practically insoluble, or insoluble, across the pH 1 to pH 7 range.

Pirtobrutinib tablets are supplied as 50 mg or 100 mg film-coated, debossed tablets for oral administration. Each tablet contains inactive ingredients of croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose and silicon dioxide. The tablet film coating material contains FD&C Blue #2, hypromellose, titanium dioxide and triacetin.

How it works: Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID bd551845-0878-49a4-860f-839b83f6b801. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate